Gastrointestinal Cancer | Oncology Newswatch

Therapy for Helicobacter Pylori Helps Prevent Metachronous Gastric Cancer

Patients with early-stage gastric cancer who receive Helicobacter pylori treatment may benefit from lower rates of metachronous gastric cancer and only mild adverse events.

Accredited CME from Imedex

Key Insights: Great Debates and Updates in GI Malignancies 2017 - Non-Colorectal Cancers

In this Key Insights activity, Dr Scott Kopetz and conference chair David H Ilson discuss the key take-home messages from the meeting, with a particular focus on non-colorectal GI cancers.

ESMO 19th World Congress on Gastrointestinal Cancer

This webcast contains the most clinically significant information on pancreatic, esophageal, gastric, anal, rectal, hepatocellular, and colorectal cancers, as well as the broader subjects of immune therapy, surgery, and multimodality therapy.

Conferences

2018 Great Debates and Updates in Gastrointestinal Malignancies Conference

On March 23rd and 24th, 2018, meeting co-chairs Axel Grothey, MD and David Ilson, MD, PhD will join 19 other expert faculty members to discuss colorectal and pancreatic cancers, rare tumors, immunotherapy and hepatobiliary cancers, among other hot topics at the 2018 Great Debates & Updates in GI Malignancies.

ASCO Gastrointestinal Cancers Symposium

Journal of Clinical Pathways provides highlights from the annual Gastrointestinal Cancers Symposium in San Francisco, California (January 19-21, 2017).

Oncology Nurse Navigators Improve GI Cancer Outcomes

At the second annual Oncology Nurse Advisor Navigation Summit (April 7-9, 2016; Orlando, FL), Teresa Labovich, MSN, RN, OCN, Penrose Cancer Center (Colorado Springs, CO), described a method by which gastrointestinal (GI) oncology nurse navigators (ONN) can play a role in improving institutional efficiency and patient outcomes.

News

Therapy for Helicobacter Pylori Helps Prevent Metachronous Gastric Cancer

Patients with early-stage gastric cancer who receive Helicobacter pylori treatment may benefit from lower rates of metachronous gastric cancer and only mild adverse events.

Profiling Metastatic Lesions, Cell-Free DNA Improves GEA Treatment Decisions

Investigating genetic variations within a primary tumor, the differences between the primary tumor and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma (GEA), according to a recent study.

Proton Beam Therapy in Older Patients With Esophageal Cancer

Researchers compared the effects of proton beam therapy plus chemotherapy vs traditional radiation therapy plus chemotherapy in older patients undergoing surgery for esophageal cancer.

Optimal Chemoradiotherapy Regimen After Curative Resection of Gastric Cancer

A recent study compared the effects of multiple adjuvant chemoradiotherapy regimens on overall survival (OS) in patients with gastric or gastroesophageal junction adenocarcinoma, published in the Journal of Clinical Oncology (online October 4, 2017; doi:10.1200/JCO.2017.74.2130).

Research in Review

Higher Dose Does Not Improve Efficacy of Gastric Cancer Treatment

A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety, according to research published in the Journal of Clinical Oncology (published online June 2017; doi:10.1200/JCO.2016.71.6852).

-----

A recent study showed that over 65% of cases of a certain tumor type were over-diagnosed or inaccurately risk-stratified, published in PLOS One (June 7, 2017;12[6]:e0179216).

-----

Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research.

-----

Administering capecitabine after surgery extends survival by a median of 17 months compared with surgery alone for patients with biliary tract cancer, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Resources

NCCN Issues Guideline Update for Esophageal, Esophagogastric Junction Cancers

The National Comprehensive Cancer Network recently released treatment guideline updates for esophageal and esophagogastric junction cancers, involving a systemic therapy in the second-line setting.

Subscribe to Gastrointestinal Cancer